Quest Diagnostics Inc. Reports Strong Financial Performance for 2024
Quest Diagnostics Inc., a leading provider of diagnostic information services, has released its annual report for 2024, revealing a solid financial performance with significant strides in revenue and operating income. The company, headquartered in Secaucus, New Jersey, reported a revenue of $10.8 billion, reflecting a 3.1% increase compared to 2023.
1. Revenue Breakdown
The revenue growth was primarily driven by the company's Diagnostic Information Services (DIS) segment, which generated approximately $9.61 billion in 2024, marking a 7.11% increase from $8.97 billion in 2023. The DIS segment accounted for about 89% of the total revenue. Conversely, the Diagnostic Services (DS) businesses saw a decline, generating $258 million, which is down 6.52% from the previous year.
Segment Performance
- U.S. Independent Lab: $7.5 billion (69.4% of total revenue)
- Employer Health Solutions: $2.3 billion (21.3% of total revenue)
- Risk Assessment Services: $0.5 billion (4.6% of total revenue)
- International: $0.5 billion (4.6% of total revenue)
The geographical focus remains predominantly on the U.S., with international revenue constituting 4.6% of total revenue.
2. Key Financial Metrics
Quest Diagnostics reported a net income of $871 million in 2024, translating to a diluted earnings per share of $8.45. This represents a notable increase from the net income of $854 million in 2023. The operating income for the year was $1.34 billion, with an operating margin of 13.5%. The gross margin was recorded at 44.6%, while the operating expense ratio stood at 30.7%, reflecting the company's commitment to operational efficiency.
| Feb 2024 | Feb 2025 | |
|---|---|---|
Net Income | 854M | 871M |
Net Income to Non-controlling Interest | 54M | 50M |
Profit | 908M | 921M |
Net Income Continuing | 882M | 902M |
Income Tax Expense | 248M | 273M |
Pretax Income | 1.13B | 1.17B |
Non-operating Income | -132M | -171M |
Operating Income | 1.26B | 1.34B |
Revenue | 9.25B | 9.87B |
Costs and Expenses | 7.99B | 8.52B |
Cost of Revenue | 6.19B | 6.62B |
Operating Expenses | 1.79B | 1.89B |
Depreciation, Depletion & Amortization | 108M | 127M |
Selling, General & Administrative | 1.64B | 1.77B |
Other Operating Expenses | 41M | 1M |
Income Statement Highlights
- Revenue: $9.87 billion
- Operating Income: $1.34 billion
- Net Income: $871 million
- Earnings Per Share: $8.45
3. Balance Sheet Overview
As of December 31, 2024, Quest Diagnostics' total assets stood at $16.15 billion, up from $14.02 billion in 2023. Current assets were reported at $2.39 billion, while non-current assets reached $13.76 billion. The company's liabilities also increased, totaling $7.78 billion, with total equity amounting to $6.81 billion.
| Feb 2024 | Feb 2025 | |
|---|---|---|
Total Assets | 14.02B | 16.15B |
Total Current Assets | 2.37B | 2.39B |
Cash and Equivalents | 686M | 549M |
Net Inventories | 190M | 188M |
Accounts Receivable | 1.21B | 1.30B |
Prepaid Expenses | 286M | 351M |
Total Non-current Assets | 11.65B | 13.76B |
Intangible Assets | 8.89B | 10.61B |
Long-term Investments | 135M | 123M |
Net PP&E | 1.81B | 2.11B |
Lease Assets | 602M | 651M |
Other Non-current Assets | 198M | 255M |
Total Liabilities and Equity | 14.02B | 16.15B |
Other Equity and Liabilities | 1.37B | 1.47B |
Temporary Equity and Redeemable Non-controlling Interest | 76M | 83M |
Total Liabilities | 6.22B | 7.78B |
Total Current Liabilities | 1.81B | 2.16B |
Accounts Payable and Accrued Liabilities | 1.35B | 1.39B |
Current Debt | 456M | 775M |
Total Non-current Liabilities | 4.41B | 5.61B |
Long-term Debt | 4.41B | 5.61B |
Total Equity and Non-controlling Interests | 6.34B | 6.81B |
Total Equity | 6.30B | 6.77B |
Non-controlling Interests | 35M | 35M |
Balance Sheet Highlights
- Total Assets: $16.15 billion
- Total Liabilities: $7.78 billion
- Total Equity: $6.81 billion
4. Cash Flow Analysis
The cash flow statement revealed a net change in cash of $-137 million, primarily due to significant investments in business acquisitions and productive assets. Net cash from operating activities was strong at $1.33 billion, bolstered by an operating profit of $921 million.
| Feb 2024 | Feb 2025 | |
|---|---|---|
Net Change in Cash | 371M | -137M |
Effect of Exchange Rate Changes | 0 | -7M |
Net Cash from Operating Activities | 1.27B | 1.33B |
Operating Profit | 908M | 921M |
Adjustment to Operating Profit | 364M | 413M |
Net Cash from Investing Activities | -1.06B | -2.54B |
Business & Interest in Affiliates | 611M | 2.16B |
Productive Assets | 408M | 425M |
Other Investing Activities | -42M | 41M |
Net Cash from Financing Activities | 160M | 1.08B |
Debt | 748M | 1.54B |
Dividends | 371M | 378M |
Equity Issuance/Repurchase | -203M | -78M |
Other Financing Activities | -14M | -3M |
Cash Flow Highlights
- Net Change in Cash: $-137 million
- Net Cash from Operating Activities: $1.33 billion
- Net Cash from Investing Activities: $-2.54 billion
5. Key Developments and Future Outlook
2024 was also a year of strategic expansion for Quest Diagnostics, with significant acquisitions aimed at enhancing its diagnostic services. Notable transactions included the acquisition of LifeLabs from OMERS and Outreach Laboratory Services from OhioHealth.
The company also successfully launched several initiatives, including expanding its health coaching services on questhealth.com, and the introduction of new blood tests aimed at identifying micronutrient deficiencies.
Leadership Changes
A key development in the company's leadership was the appointment of Steven M. Haden as Chief Financial Officer, effective January 1, 2023. This change comes as the company continues to innovate and adapt to the evolving healthcare landscape.
Legal Proceedings
While Quest is involved in various legal proceedings, the company maintains that it does not expect any material losses from these matters. As of the end of 2024, reserves for legal matters totaled $4 million.
6. Conclusion
In summary, Quest Diagnostics Inc. demonstrated robust financial performance in 2024, with growth in key revenue segments and strategic investments paving the way for future success. As the company continues to enhance its offerings and expand its market presence, stakeholders can remain optimistic about its trajectory in the ever-evolving diagnostic services industry.
